Compound heterozygosity (G71R/R140H) in the lecithin:cholesterol acyltransferase (LCAT) gene results in an intermediate phenotype between LCAT-deficiency and fish-eye disease


      The esterification of free cholesterol (FC) in plasma, catalyzed by the enzyme lecithin:cholesterol acyltransferase (LCAT; EC, is a key process in lipoprotein metabolism. The resulting cholesteryl esters (CE) represent the main core lipids of low (LDL) and high density lipoproteins (HDL). Primary (familial) LCAT-deficiency (FLD) is a rare autosomal recessive genetic disease caused by the complete or near absence of LCAT activity. In fish-eye disease (FED), residual LCAT activity is still detectable. Here, we describe a 32-year-old patient with corneal opacity, very low LCAT activity, reduced amounts of CE (low HDL-cholesterol level), and elevated triglyceride (TG) values. The lipoprotein pattern was abnormal with regard to lipoprotein composition and concentration, but distinct lipoprotein classes were still present. Despite of typical features of glomerular proteinuria, creatinine clearance was normal. DNA sequencing and restiction fragment analyses revealed two separate mutations in the patient's LCAT gene: a previously described G to A transition in exon 4 converting Arg140 to His, inherited from his mother, and a novel G to C transversion in exon 2 converting Gly71 to Arg, inherited from his father, indicating that M.P. was a compound heterozygote. Determination of enzyme activities of recombinant LCAT proteins obtained upon transfection of COS-7 cells with plasmids containing G71R-LCAT or wild-type LCAT cDNA revealed very low α- and absence of β-LCAT activity for the G71R mutant. The identification of the novel G71R LCAT mutation supports the proposed molecular model for the enzyme implying that the “lid” domain at residues 50–74 is involved in enzyme:substrate interaction. Our data are in line with the hypothesis that a key event in the etiology of FLD is the loss of distinct lipoprotein fractions.


      LCAT (lecithin:cholesterol acyltransferase), FLD (familial LCAT-deficiency), FED (fish-eye disease), FC (free (unesterified) cholesterol), TC (total cholesterol), CE (cholesteryl ester), HDL (high density lipoproteins), (V)LDL ((very) low density lipoproteins), αlMiG (αl-microglobulin), Alb (albumin), Trf (transferrin), ECC (endogenous creatinine clearance), WT (wild type), CETP (cholesteryl ester transfer protein)


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Yokoyama S.
        Release of cellular cholesterol: molecular mechanism for cholesterol homeostasis in cells and in the body.
        Biochim Biophys Acta. 2000; 1529: 231-244
        • Brown M.S.
        • Goldstein J.L.
        A receptor-mediated pathway for cholesterol homeostasis.
        Science. 1986; 232: 34-47
        • Fielding C.J.
        • Fielding P.E.
        Molecular physiology of reverse cholesterol transport.
        J Lipid Res. 1995; 36: 211-228
        • Hill S.A.
        • McQueen M.J.
        Reverse cholesterol transport—a review of the process and its clinical implications.
        Clin Biochem. 1997; 30: 517-525
        • Klein H.G.
        • Lohse P.
        • Pritchard P.H.
        • et al.
        Two different allelic mutations in the lecithin-cholesterol acyltransferase gene associated with the fish eye syndrome. Lecithin-cholesterol acyltransferase (Thr123 → Ile) and lecithin-cholesterol acyltransferase (Thr347 → Met).
        J Clin Invest. 1992; 89: 499-506
        • Gotoda T.
        • Yamada N.
        • Murase T.
        • et al.
        Differential phenotypic expression by three mutant alleles in familial lecithin:cholesterol acyltransferase deficiency.
        Lancet. 1991; 338: 778-781
        • Kuivenhoven J.A.
        • Pritchard H.
        • Hill J.
        • et al.
        The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes.
        J Lipid Res. 1997; 38: 191-205
        • Gjone E.
        • Norum K.R.
        Familial serum cholesterol ester deficiency. Clinical study of a patient with a new syndrome.
        Acta Med Scand. 1968; 183: 107-112
        • Peelman F.
        • Vinaimont N.
        • Verhee A.
        • et al.
        A proposed architecture for lecithin cholesterol acyl transferase (LCAT): identification of the catalytic triad and molecular modeling.
        Protein Sci. 1998; 7: 587-599
        • Peelman F.
        • Verschelde J.L.
        • Vanloo B.
        • et al.
        Effects of natural mutations in lecithin:cholesterol acyltransferase on the enzyme structure and activity.
        J Lipid Res. 1999; 40: 59-69
        • Carlson L.A.
        • Philipson B.
        Fish-eye disease. A new familial condition with massive corneal opacities and dyslipoproteinaemia.
        Lancet. 1979; 2: 922-924
        • Frohlich J.
        • Hoag G.
        • McLeod R.
        • et al.
        Hypoalphalipoproteinemia resembling fish eye disease.
        Acta Med Scand. 1987; 221: 291-298
        • Funke H.
        • von Eckardstein A.
        • Pritchard P.H.
        • et al.
        A molecular defect causing fish eye disease: an amino acid exchange in lecithin-cholesterol acyltransferase (LCAT) leads to the selective loss of alpha-LCAT activity.
        Proc Natl Acad Sci USA. 1991; 88: 4855-4859
        • Kastelein J.J.
        • Pritchard P.H.
        • Erkelens D.W.
        • et al.
        Familial high-density-lipoprotein deficiency causing corneal opacities (fish eye disease) in a family of Dutch descent.
        J Intern Med. 1992; 231: 413-419
        • Steyrer E.
        • Durovic S.
        • Frank S.
        • et al.
        The role of lecithin:cholesterol acyltransferase for lipoprotein (a) assembly. Structural integrity of low density lipoproteins is a prerequisite for Lp(a) formation in human plasma.
        J Clin Invest. 1994; 94: 2330-2340
        • Steyrer E.
        • Haubenwallner S.
        • Horl G.
        • et al.
        A single G to A nucleotide transition in exon IV of the lecithin:cholesterol acyltransferase (LCAT) gene results in an Argl40 to His substitution and causes LCAT-deficiency.
        Hum Genet. 1995; 96: 105-109
        • Skretting G.
        • Prydz H.
        An amino acid exchange in exon I of the human lecithin: cholesterol acyltransferase (LCAT) gene is associated with fish eye disease.
        Biochem Biophys Res Commun. 1992; 182: 583-587
        • Kozak M.
        Structural features in eukaryotic mRNAs that modulate the initiation of translation.
        J Biol Chem. 1991; 266: 19867-19870
        • Steyrer E.
        • Kostner G.M.
        Activation of lecithin: cholesterol acyl transferase by apolipoprotein D: comparison of proteoliposomes containing apolipo-protein D, A-I, or C-I.
        Biochim Biophys Acta. 1988; 958: 484-491
        • Bligh E.G.
        • Dyer W.J.
        A rapid method of total lipid extraction and purification.
        Can J Med Sci. 1959; 37: 911-917
        • Porte Jr., D.
        • Havel R.J.
        The use of cholesterol-4-C14-labeled lipoproteins as a tracer for plasma cholesterol in the dog.
        J Lipid Res. 1961; 2: 357-362
        • Glomset J.A.
        • Wright J.L.
        Some properties of a cholesterol esterifying enzyme in human plasma.
        Biochim Biophys Acta. 1964; 89: 266-276
        • Stokke K.T.
        • Norum K.R.
        Determination of lecithin:cholesterol acyltransfer in human blood plasma.
        Scand J Clin Lab Invest. 1971; 27: 21-27
        • Wallentin L.
        • Vikrot O.
        Evaluation of an in vitro assay of lecithin:cholesterol acyl transfer rate in plasma.
        Scand J Clin Lab Invest. 1975; 35: 661-667
        • Rajaram O.V.
        • Barter P.J.
        Reactivity of human lipoproteins with purified lecithin: cholesterol acyltransferase during incubations in vitro.
        Biochim Biophys Acta. 1985; 835: 41-49
        • Barter P.J.
        • Hopkins G.J.
        • Gorjatschko L.
        Comparison of human plasma low-and high-density lipoproteins as substrates for lecithin: cholesterol acyltransferase.
        Biochim Biophys Acta. 1984; 792: 1-5
        • Channon K.M.
        • Clegg R.J.
        • Bhatnagar D.
        • et al.
        Investigation of lipid transfer in human serum leading to the development of an isotopic method for the determination of endogenous cholesterol esterification and transfer.
        Atherosclerosis. 1990; 80: 217-226
        • Guerin M.
        • Dachet C.
        • Goulinet S.
        • et al.
        Familial lecithin:cholesterol acyltransferase deficiency: molecular analysis of a compound heterozygote: LCAT (Arg147 → Trp) and LCAT (Tyrl71 Stop).
        Atherosclerosis. 1997; 131: 85-95
      1. Calabresi L, Pisciotta L, Costantin A, et al. The molecular basis of lecithin:cholesterol acyltransferase deficiency syndromes. A comprehensive study of molecular and biochemical findings in 13 unrelated italian families. Arterioscler Thromb Vase Biol. 2005; [Epub ahead of print].

        • Vanloo B.
        • Peelman F.
        • Deschuymere K.
        • et al.
        Relationship between structure and biochemical phenotype of lecithin:cholesterol acyltransferase (LCAT) mutants causing fish-eye disease.
        J Lipid Res. 2000; 41: 752-761
        • Jauhiainen M.
        • Stevenson K.J.
        • Dolphin P.J.
        Human plasma lecithin-cholesterol acyltransferase. The vicinal nature of cysteine 31 and cysteine 184 in the catalytic site.
        J Biol Chem. 1988; 263: 6525-6533
        • Miida T.
        • Zhang B.
        • Obayashi K.
        • et al.
        T13M mutation of lecithin-cholesterol acyltransferase gene causes fish-eye disease.
        Clin Chim Acta. 2004; 343: 201-208
        • Klein H.G.
        • Santamarina-Fojo S.
        • Duverger N.
        • et al.
        Fish eye syndrome: a molecular defect in the lecithin-cholesterol acyltransferase (LCAT) gene associated with normal alpha-LCAT-specific activity. Implications for classification and prognosis.
        J Clin Invest. 1993; 92: 479-485
        • Kuivenhoven J.A.
        • Stalenhoef A.F.
        • Hill J.S.
        • et al.
        Two novel molecular defects in the LCAT gene are associated with fish eye disease.
        Arterioscler Thromb Vase Biol. 1996; 16: 294-303
        • Kuivenhoven J.A.
        • Weibusch H.
        • Pritchard P.H.
        • et al.
        An intronic mutation in a lariat branchpoint sequence is a direct cause of an inherited human disorder (fish-eye disease).
        J Clin Invest. 1996; 98: 358-364
        • Le Goff W.
        • Guerin M.
        • Chapman M.J.
        Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia.
        Pharmacol Ther. 2004; 101 ([Review]): 17-38
        • Guerin M.
        • Dolphin P.J.
        • Chapman M.J.
        Familial lecithin:cholesterol acyltrans-ferase deficiency: further resolution of lipoprotein particle heterogeneity in the low density interval.
        Atherosclerosis. 1993; 104: 195-212
        • Frohlich O.K.J.
        Role of lecithin:cholesterol acyltransferase and apolipoprotein A-I in cholesterol esterification in lipoprotein-X in vitro.
        J Lipid Res. 1995; 36: 2344-2354